` LBT (LBT Innovations Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

LBT
vs
S
S&P/ASX 300

Over the past 12 months, LBT has underperformed S&P/ASX 300, delivering a return of +6% compared to the S&P/ASX 300's +9% growth.

Stocks Performance
LBT vs S&P/ASX 300

Loading
LBT
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
LBT vs S&P/ASX 300

Loading
LBT
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
LBT vs S&P/ASX 300

Loading
LBT
S&P/ASX 300
Add Stock

Competitors Performance
LBT Innovations Ltd vs Peers

S&P/ASX 300
LBT
ABT
ISRG
BSX
SYK
Add Stock

LBT Innovations Ltd
Glance View

Market Cap
29.9m AUD
Industry
Health Care

LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia. The company went IPO on 2006-07-31. The firm is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets. The firm's product pipeline includes The Automated Plate Assessment System for antimicrobial resistance (APAS-AMR), WoundVue, Biofilm, Automated Gram Stain Assessment and MicroStreak. The firm's Automated Plate Assessment System (APAS) Independence is a platform technology that automates culture-plate screening and interpretation. APAS Independence screens, interprets, and sorts these plates, overcoming the bottleneck in lab workflows and freeing up microbiologist's time. Its APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates.

LBT Intrinsic Value
0.002 AUD
Overvaluation 86%
Intrinsic Value
Price
Back to Top